Phase 2a will be a randomized, vehicle controlled, parallel group study designed to assess the safety, tolerability and preliminary efficacy of DRM01B topical gel in subjects with acne vulgaris. Approximately 100 subjects will be enrolled and treated with study drug for 12 weeks.